This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.
The 45th Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting (ASM) brought together over 300 delegates on Gadigal land in Sydney from 14 to 16 August 2024. The ASM theme ‘Caring...
Overview of Key Trials Shaping the Treatment Landscape in Australia...
Approximately one in five urothelial carcinomas are muscle-invasive at initial diagnosis.1 Standard management for muscle-invasive urothelial carcinoma (MIUC) is bladder sparing therapy or radical...
The era of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) has rapidly transformed the treatment landscape for patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor...
Up to 30% of patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) high-risk early breast cancer (EBC) will experience distant disease recurrence,...
Adult patients with acute lymphoblastic leukaemia (ALL) have a poorer prognosis in terms of cure rate, compared to the paediatric ALL population.1, 2 While adults achieve relatively high initial...
Cancers associated with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) status account for >70% of all breast cancers.1 About 40% of HR+/HER2- cancers...
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN), characterized by ineffective clonal hematopoiesis, splenomegaly, worsening bone marrow fibrosis, cytopenias, and transformation to...
Concurrent chemoradiotherapy (cCRT) with platinum-based chemotherapy has traditionally been the first-line standard of care (SOC) for patients with stage III unresectable non-small cell lung cancer...
Prolonged overall survival (OS) is the key goal of treatment for patients with metastatic breast cancer (mBC),1 and remains a gold standard primary endpoint for oncology trials.2 In some patient...